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Summary We evaluated the effectiveness of inactivated inﬂuenza vaccine in per-
sons aged ≥45 years with co-morbidities (including essential hypertension) likely
to have prompted consideration of prophylactic statin therapy. Using case—control
analyses, we measured the impact of vaccination on General Practitioner (GP)
reported new episodes of illness for clinically diagnosed inﬂuenza-like illness (ILI)
and total acute respiratory infection (TARI) during eight consecutive winters,
adjusting for potential confounders using multivariable techniques. Although the
study failed to demonstrate the effectiveness of inﬂuenza vaccine, we identiﬁed
important potential confounding related to a greater likelihood of vaccinees than
non-vaccinees to consult with a GP for respiratory infections. Future researchers
should consider and account for this phenomenon.
© 2010 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier
.
oLtd. All rights reserved
ntroductioneasonal inﬂuenza is regularly associated with
xcess winter morbidity and mortality. The risks
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oi:10.1016/j.jiph.2010.09.007f mortality, hospitalisation and complications are
levated in the elderly, young children and individ-
als with high-risk chronic illnesses [1]. In the UK
nnual inﬂuenza vaccination is recommended for
he elderly, and children or adults in clinical risk
roups [2].
The study of inﬂuenza vaccine effective-
ess is fraught with methodological difﬁculties,
ost notably: year-on-year variations in matching
Sciences. Published by Elsevier Ltd. All rights reserved.
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between wild-type and vaccine viruses; variations
in epidemic timing and intensity; selection of
outcome measures; the non-acceptability of ran-
domised trials in elderly and high-risk subjects; and
residual confounding in observational studies. Yet
reliable estimates are important for deﬁning and
reviewing vaccination policy. To address the issue of
inter-seasonal variations, we determined the effec-
tiveness of inﬂuenza vaccination over a sustained
eight-year period, whilst attempting to address
issues of potential bias and residual confounding
using a large primary care clinical database.
Although studies suggest that inﬂuenza vaccine
reduces cardiovascular events, the effectiveness of
vaccine in persons with risk factors for cardiac dis-
ease has not been studied extensively in isolation
[3,4].
Methods
We measured the impact of inﬂuenza vaccination
on GP reported episodes of illness for two clinically-
diagnosed outcomes: inﬂuenza-like illness (ILI) and
total acute respiratory infection (TARI) = (ILI + acute
respiratory infection (ARI) + pneumonia), during
eight consecutive winters from 1998/99 to 2005/06.
In addition, we examined two time periods: each
entire winter season (deﬁned as 1st November
to 31st March); and those (variable) portions of
each winter season when inﬂuenza virus was known
to be actively circulating in the community —
‘inﬂuenza-restricted periods’ (as determined by
National Clinical and Virological Surveillance) [5].
We studied patients aged 45 years and over
who were registered with one of 25 GP practices
within the network of the Royal College of General
Practitioners (RCGP) Weekly Returns Service (WRS)
and who had co-morbidities (including essential
hypertension) likely to have prompted considera-
tion of prophylactic statin therapy. A case—control
methodology was employed. Data were extracted
from electronic case records using Miquest Enquirer
(© Crown copyright), and analysed in Stata® v.10
(StataCorp Inc.).
Cases of ILI, ARI, and pneumonia were identiﬁed
using Read Codes, mapped onto the International
Classiﬁcation of Diseases (ICD-9). ILI, ARI and pneu-
monia were then combined to compute TARI. Cases
which occurred 14 days or less after receiving
inﬂuenza vaccination were excluded from further
analysis because it was not possible to conclude
that such persons would have had an opportunity to
seroconvert before infection [6]. Up to ﬁve controls
(depending on suitable individuals) were randomly
selected for each case, matched for age (year of
R
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irth), sex and general practice, who did not con-
ult their GP with ILI or TARI during the same winter
eason.
Data on chronic illnesses were identiﬁed from
ondition-speciﬁc entries in the GP records and
rouped as: chronic pulmonary disease (including
sthma); chronic cardiovascular disease (including
ypertension, ischaemic heart disease, hyperlipi-
emia, and other circulatory diseases); diabetes
ellitus; hypothyroidism; and neoplasia. We also
xtracted data on demography and inﬂuenza vacci-
ation each winter.
For a measure of effect identiﬁed from previous
iterature: 63% vaccine effectiveness — equiva-
ent to an odds ratio of 0.37, and providing
0% power at 5% signiﬁcance (two-tailed), and a
ase:control ratio of 1:5, with vaccine uptake in
ontrols between 30.7% (in 1999—2000) and 55%
in 2003—2004), we estimated a requirement for
3—82 cases per season.
tatistical analysis
nivariate (screening) analyses were carried out
sing conditional logistic regression to exam-
ne the association and the effect of each
xplanatory variable on the risk of ILI and TARI
Wald test). Subsequently, a series of multivari-
ble conditional logistic regression models for
matched case—control study were created in
hich co-morbid conditions were forced in to
he model. Finally, inﬂuenza vaccine status was
dded. The odds ratio produced was used to cal-
ulate vaccine effectiveness as one minus the odds
atio in vaccinated subjects, multiplied by 100;
E = (1−OR)× 100. Each season was analysed sep-
rately, followed by a ﬁnal analysis of the whole
tudy period after removal of patients who became
case in more than one season. We considered that
ny odds ratio greater than one represented zero
ercent vaccine effectiveness, because it is not bio-
ogically plausible that inactivated inﬂuenza vac-
ines of the type used in the UK can cause inﬂuenza.
Analyses are presented in detail for winter
999/2000, because this season offered the highest
tatistical power (93%) and was generally regarded
s the most severe within the study period. Sum-
ary data are provided for all other years.esults
ur study included 353 ILI cases and 1711 con-
rols who sought care in 25 clinical facilities in
ngland and Wales in the period from 1998/1999
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Table 2 Demography, chronic disease and vacci-
nation status for ILI cases and controls, 1999/2000
season.
Variables Frequency (percentage)
Cases
(n = 91)
Controls
(n = 417)
Age
45—<65 63 (69.2) 285 (68.3)
65—<75 17 (18.7) 83 (19.9)
75 more 11 (12.1) 49 (11.8)
Sex
Male 36 (39.6) 158 (37.9)
Female 55 (60.4) 259 (62.1)
Diabetes 12 (13.2) 48 (11.5)
Hypertension 42 (46.2) 213 (51.1)
Ischemic heart disease 15 (16.5) 75 (18.0)
Other circulatory disease 24 (26.4) 101(24.2)
COPD 25 (27.5) 113 (27.1)
Hyperlipidemia 12 (13.2) 60 (14.4)
Hypothyroidism 12 (13.2) 50 (12.0)
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eigure 1 Percentage inﬂuenza vaccine uptake from
998/99 to 2005/06.
o 2005/2006 (Table 3). The number of persons
ncluded each year varied ranging from 30 in
002/03 to 91 in 1999/2000 for cases, and the num-
er of matched controls varied ranging from 150
o 417. Likewise, we studied 2222 TARI cases and
0785 controls for the same period of time. The
umber of cases included each year varied rang-
ng from 106 in 1998/1999 to 388 in 2002/03, and
he number of matched controls ranged from 530
o 1902.
accine uptake
accine uptake among study subjects rose grad-
ally from a low-point of 34% in 1999/2000 to
6% in 2005/06 (Fig. 1). Over the same period,
he rate of GP reported episodes of ILI in the
tudy population decreased from 13.4/1000/season
n 1999/2000 to 3.3/1000/season in 2005/06; the
pisode rate for TARI was more consistent rang-
ng from 35.9/1000/season to 31.4/1000/season
espectively (Table 1).
nﬂuenza-like illnessor the 1999/2000 winter season, 91 eligible cases
f ILI were identiﬁed, along with 417 controls.
able 2 shows the demography and distribution
f chronic illnesses between cases and controls.
a
0
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Table 1 ILI and TARI case numbers and seasonal consultati
Season Inﬂuenza-like illness (ILI)
Number Rate/1000/season
1998/99 43 6.0
1999/2000 91 13.4
2000/01 47 6.2
2001/02 36 4.5
2002/03 30 3.5
2003/04 33 3.7
2004/05 42 4.6
2005/06 31 3.3Neoplasia 4 (4.39) 20 (1.17)
Inﬂuenza vaccine 25 (27.5) 124 (29.7)
pproximately two-thirds of cases and controls
ere aged 45—65 and about 60% were females.
wenty-ﬁve of 91 cases (27.5%) had received
999/2000 seasonal inﬂuenza vaccine, compared
ith 124 of 417 controls (29.7%), p = 0.66, odds
atio = 0.89 (95% CI 0.53—1.48); unadjusted vaccine
ffectiveness was therefore estimated at 11% (95%
I 0—47%).
The ﬁnal conditional logistic regression model
or the outcome of ILI is shown in Table 3. Each
isk factor is adjusted for all of the other vari-
bles, but none reached statistical signiﬁcance.
nﬂuenza vaccine status did not signiﬁcantly inﬂu-
nce the likelihood of ILI consultation (p = 0.91)
nd vaccine effectiveness was estimated to be
—46%.
The multivariable analysis was then repeated,
estricted to that part of the 1999/2000 season
on rates from 1998/99 to 2005/06.
Total acute respiratory infection (TARI)
Number Rate/1000/season
106 14.9
244 35.9
264 34.9
308 38.4
382 45.1
314 35.2
307 33.7
297 31.4
162 A.B. Hashim et al.
Table 3 Multivariable model for risk factors for ILI
consultation during the 1999/2000 winter season.
Variable OR 95% CI
Diabetes 1.25 0.62—2.52
Hypertension 0.79 0.46—1.33
Ischemic heart disease 0.89 0.45—1.73
Other circulatory diseases 1.09 0.62—1.92
COPD 0.94 0.53—1.68
Hyperlipidemia 0.91 0.45—1.83
Hypothyroidism 1.07 0.52—2.20
Neoplasm 0.87 0.28—2.69
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*Based on 91 cases and 417 matched controls; each variable
is adjusted for all others in the model.
when inﬂuenza viruses were known to be circu-
lating; Fig. 2 shows this period started in week
50, 1999 and lasted until week 6, 2000 based
on a threshold of 50 ILI consultations/105 popula-
tion/week. By these means, 21 cases of ILI and their
corresponding matched controls were excluded
from the analysis, leaving 70 cases and 322 controls.
The ﬁnal model (available on request) produced
odds ratio for vaccination of 1.03 against ILI (95%
CI 0.54—1.94); vaccine effectiveness: 0—46%. No
other risk factors were signiﬁcant.
Summary data for all other individual seasons
are shown in Table 4 (models available on request).
When all eight seasons were pooled (after exclusion
of cases that appeared in more than one season),
themulti-year combined dataset produced an unad-
justed OR 1.09 (95% CI 0.83—1.42) equating to a
vaccine effectiveness of 0—17% and after control-
ling for confounder the adjusted odds ratio was
1.21 (95% C 0.65—2.25), equating to a vaccine
effectiveness of 0—35%. No signiﬁcant effects of
inﬂuenza vaccine against GP consultations for ILI
were observed in any year.
Figure 2 Inﬂuenza active period during the 1999/2000
season in England as determined by virus detections from
Health Protection Agency laboratories and consultation
rates for ILI in RCGP sentinel practices.
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otal acute respiratory tract infections
n a secondary analysis we combined consultations
or acute respiratory infections with pneumo-
ia and ILI to produce a composite category
abelled TARI. In 1999/2000, 244 eligible cases
ere identiﬁed and 1189 controls were matched.
inety-two of the 244 cases (37.7%) received
easonal inﬂuenza vaccine compared with 492 of
189 controls (41.4%), p = 0.10; this produced an
nadjusted odds ratio of 1.30 (95% CI 0.94—1.79)
quivalent to 0—4% vaccine effectiveness.
In the univariate screening analyses, diabetes
as a signiﬁcant risk factor for TARI consultation:
R = 1.47 (95% CI 1.03—2.11), p = 0.011. However,
n the ﬁnal multivariable model (244 cases, 1189
ontrols: available on request), it was no longer
igniﬁcant. The risk of consultation for TARI was
ot signiﬁcantly affected by inﬂuenza vaccination
OR = 1.23, 95% CI 0.89—1.72), p = 0.20; vaccine
ffectiveness: 0—11%. After restriction of the
odel to the inﬂuenza active period, 90 cases of
RI, 21 cases of ILI, and two of pneumonia were
ost, leaving 131 cases and 630 controls. The ﬁnal
ime-restricted model produced an odds ratio for
accination of 1.01 (95% CI 0.63—1.62), p = 0.95;
accine effectiveness 0—37%; no other risk factors
ere signiﬁcant.
Data from the remaining individual seasons
re summarised in Table 4 (models available on
equest). The multi-year combined dataset pro-
uced an unadjusted odds ratio of 1.47 (95% C
.30—1.66), equating to a vaccine effectiveness
f 0% and an adjusted odds ratio of 1.39 (95%
1.22—1.57), equating to a vaccine effective-
ess of 0%. In seasons 1998/99, 2001/02, 2002/03,
004/05, and 2005/06, vaccinees were more likely
han non-vaccinees to consult a GP with TARI over
he whole length of the winter season.
iscussion
his study indicates the important potential con-
ounding that is inherent when observational
tudies are used to measure the effectiveness of
nﬂuenza vaccine. Our data revealed consistently
hat vaccinees were more likely than non-vaccinees
o consult a GP for TARI. This provides a very clear
ignal that the likelihood to consult a GP may be
ifferent between vaccinees and non-vaccinees,
specially in the presence of co-morbid condi-
ions, for which vaccine is recommended. Despite
hese difﬁculties, we examined the effectiveness
f inﬂuenza vaccine over eight consecutive win-
er seasons, including year-on-year variability and
ﬁ
v
t
s
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verall effectiveness, measured across the whole
tudy period. Many previous studies have performed
nalyses based on far fewer inﬂuenza seasons,
ften just one; however considerable variability is
ossible in the antigenic match between circulat-
ng inﬂuenza viruses and vaccine strains, which in
urn produces variable estimates of effectiveness
etween different locations and seasons [7,8]. In
act, during the study period, the degree of anti-
enic matching between vaccine and virus strains
n the UK was good in all seasons except 2003/04
nd 2005/06 when there were moderate H3N2
nd B vaccine component mismatches respectively
P. Sebastianpillai, HPA: personal communication,
008). A case—control approach, based on clinically
eﬁned outcomes has been used successfully before
n the UK revealing 41%, and 33% vaccine effective-
ess against, mortality and hospitalisations [9,10].
imilarly, a large retrospective cohort study based
n general practitioner records revealed 75% effec-
iveness against mortality [11].
In this study, the 25 participating general prac-
ices provided routine sentinel surveillance data
o the RCGP-WRS; so practitioners were well
ehearsed in classifying clinical diagnoses of ILI, ARI
nd pneumonia making diagnoses potentially more
eliable than in non-surveillance centres. The out-
ome measures used in this study were GP episodes
or clinically diagnosed ILI, and a broader compo-
ition of ILI, ARI and pneumonia — denoted total
cute respiratory tract infection (TARI). It was not
ossible to conﬁrm virologically the extent to which
hese consultations were in fact due to inﬂuenza
irus infection. Outside of speciﬁc emergency situ-
tions, e.g. the early stages of the 2009 inﬂuenza
/H1N1 pandemic, the taking of diagnostic virolog-
cal specimens in patients presenting with acute
espiratory infection is extremely rare in British
eneral practice [9]. However we also performed
nalyses restricted to those time periods when
nﬂuenza was known to be circulating actively in
he community, as judged by virus isolations from
ealth Protection Agency laboratories, and periods
f peak clinical activity determined by new episode
ates in RCGP-WRS practices. During such periods it
as been previously described that the accuracy of
linical diagnosis of ILI increases [12]; nevertheless
t is likely that only a minority of TARI cases diag-
osed clinically had true inﬂuenza virus infection,
articularly when analysed as a group across the
ntire winter season. The effect of this misclassi-
cation bias would be to underestimate inﬂuenza
accine effectiveness. Even though it was possible
o draw from the records of over 7000 patients per
eason, this approach still yielded relatively small
umbers of ILI cases in many seasons, resulting in
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some under-powering, although the analyses based
on TARI had more than adequate statistical power.
Our results revealed a steady rise in vaccine
uptake ﬁgures from 38% in 1998/99 to 56% in
2005/06. Increases in community awareness, a pol-
icy change towards universal vaccination of the
elderly (in 1999/2000), and the setting of vaccina-
tion targets will all have contributed towards that
rise. In contrast, ILI and TARI consultations did not
decline appreciably after 1999/2000 in the study
population. These ﬁndings are consistent with US
studies which have observed that crude excess mor-
tality among elderly people continued to rise during
1980s and 1990s in spite of the increase in vaccine
coverage from 15% to 65% since 1980 [13,14].
Results from the ﬁrst case—control study, based
on ILI outcome revealed different year-to-year
vaccine effectiveness with adjusted odds ratios
(point estimates) ranging from 0.69 in 2003/04 to
2.05 in 1998/99 for whole season analyses, and
from 0.56 to 2.44 for inﬂuenza-restricted periods.
However, in 10 of 16 calculations, the odds ratio
was below unity (suggesting vaccination was effec-
tive) but failed to reach signiﬁcance, presumably
due to the effect of small numbers. Taken over all
eight winter seasons combined, the adjusted odds
ratio for the effect of vaccination on ILI was 1.21
(95% CI 0.65—2.25), consistent with overall vaccine
effectiveness of 0—35%. In contrast, for TARI, the
adjusted odds ratios (point estimates) ranged from
1.23 to 1.98 and from 1.01 to 1.80 respectively
across individual seasons. Over all eight seasons,
the adjusted odds ratio was 1.39 (95% CI 1.22—1.57)
consistent with 0% vaccine effectiveness against
TARI. More importantly, all analyses suggested that
vaccinated subjects were more likely to consult
a GP with TARI, with signiﬁcant effects noted in
1998/99, 2001/02, 2002/03 and 2004/05.
The ﬁndings of this study should be interpreted
in the light of the methodological issues inherent
in the use of observational studies to measure
inﬂuenza vaccine effectiveness, and which we
have highlighted through our approach. Firstly,
during inﬂuenza seasons that are less severe in
intensity (such as some in this study) there are
fewer cases of clinically identiﬁable ILI than might
be anticipated; and the illness might be less
easily distinguishable from other acute respiratory
infections, resulting in cases of inﬂuenza that were
classiﬁed as ARI not ILI. Taken together, these phe-
nomena increase the potential for under-powering
of studies, as occurred in a number of winter
seasons in the study, and thereby the potential
for underestimation of vaccine effectiveness,
which may well have also occurred. In contrast,
alternative methodologies which use virologically
A
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onﬁrmed inﬂuenza as the principle outcome
ontinue to report vaccine effectiveness of around
0% [15,16]. Our study was conﬁned to patients
ver 45 years of age with co-morbid conditions
mainly cardiovascular conditions) likely to have
rompted previous consideration of prophylactic
tatin therapy; as such, the ﬁndings should not be
eneralised more widely. Whilst using TARI as an
utcome measure might overcome the problem
f missing milder inﬂuenza infections that are
nrecognised as ILI, the category seems too broad
o be useful in assessing vaccine effectiveness.
In reviewing the effectiveness of inﬂuenza vac-
ine in the elderly, Simonsen et al. highlighted
he narrowness of the evidence base in this age
roup and the potentially untrustworthy nature
f data from observational studies, especially
arge retrospective studies [13]. These types of
tudy unfortunately contribute the ‘lion’s share’ of
vailable evidence. Simonsen commented on the
oubtfulness of these ﬁndings; for instance, in indi-
iduals living in the community, vaccines were truly
ffective for the prevention of non-speciﬁc out-
omes such as death from all causes, but not for the
revention of inﬂuenza or death caused by pneumo-
ia and inﬂuenza. In 1994, Govaert et al. overcame
thical constraints to perform the largest and prob-
bly best ever designed placebo-controlled RCT in
olland; 1838 healthy elderly people (aged 60 and
ver) were randomly assigned to placebo or inacti-
ated inﬂuenza vaccine. There was a 50% reduction
95% C 35—61) in laboratory conﬁrmed inﬂuenza
17]. These two studies, and our own data, provide
clear signal that future assessments of inﬂuenza
accine effectiveness, whether retrospective or
rospective, need to be supported by analyses
ased on virologically conﬁrmed outcomes. Our
ata also illustrate a separate but important pit-
all relating to the different propensity to consult
or TARI between vaccinees and non-vaccinees; this
hould be adjusted for, irrespective of whether or
ot the primary outcome is virologically or clini-
ally deﬁned. This point is especially relevant in
opulations with underlying comorbidities. In the
eantime, until the data from new studies are con-
olidated [15,16,18], elderly and high-risk people
hould continue to be vaccinated against inﬂuenza;
ven a vaccine with modest effectiveness may well
ontribute a large public health effect [19].cknowledgements
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